Full Dose-Escalation Data Show Continued High Response Rates and Favorable Safety Profile of ISB 2001, a First-in-Class BCMA × CD38 × CD3 Trispecific Antibody, for the Treatment of Relapsed/ Refractory Multiple Myeloma

Ichnos Glenmark Innovation Germany France England United Kingdom United States of America New York

View original content:https://www.prnewswire.co.uk/news-releases/full-dose-escalation-data-show-continued-high-response-rates-and-favorable-safety-profile-of-isb-2001-a-first-in-class-bcma-O-cd38-O-cd3-trispecific-antibody-for-the-treatment-of-relapsedrefractory-multiple-myeloma-302470987.html